’Explosive’ growth in foreign drug testing raises ethical questions
Peek inside any American family's medicine cabinet and you're likely to find a drug that was tested in a foreign country. Pharmaceutical companies have been shifting research overseas for years and the number of foreign trials has skyrocketed. The Department of Health and Human Services reports more than a 2,000% increase in the number of foreign trials for U.S. drugs over the past two decades. In 2008, about 80% of drug applications approved by the Food and Drug Administration contained data from foreign clinical trials. The growth in developing countries and emerging economies in particular has been "explosive" said Arthur Caplan, MD, director of the Center for Bioethics at University of Pennsylvania's Perelman School of Medicine. Caplan explained the appeal of holding clinical trials in developing countries and the ethical issues raised by this research trend.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- Carondelet to Pay $35M to Settle Fraud Allegations
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- CA Powers Up $80M HIE to 'Create Value in the Data'